---
title: "Radiopharm teams up with Siemens Healthineers to manufacture, distribute RAD101 doses for US Phase 3 trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296098148.md"
description: "Radiopharm Theranostics partnered with Siemens Healthineers to manufacture and distribute 18F-labeled RAD101 doses for a U.S. Phase 3 trial targeting suspected recurrent brain metastases post-radiotherapy. This collaboration supports the planned registrational study ahead of an FDA End-of-Phase 2 meeting scheduled for October 1, 2026."
datetime: "2026-08-17T11:31:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296098148.md)
  - [en](https://longbridge.com/en/news/296098148.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296098148.md)
generator: "portal-rs"
---

# Radiopharm teams up with Siemens Healthineers to manufacture, distribute RAD101 doses for US Phase 3 trial

-   Radiopharm Theranostics entered a partnership with Siemens Healthineers to manufacture, distribute 18F-labeled RAD101 doses for a U.S. Phase 3 trial. \* Supply support targets a planned registrational study for RAD101, an F-18 PET imaging agent for suspected recurrent brain metastases post-radiotherapy. \* Collaboration comes ahead of an FDA End-of-Phase 2 meeting set for Oct. 1, 2026 to align Phase 3 design. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608170730PRIMZONEFULLFEED1001257938) on August 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [RADX.US](https://longbridge.com/en/quote/RADX.US.md)
- [SHL.DE](https://longbridge.com/en/quote/SHL.DE.md)

## Related News & Research

- [Radiopharm reports positive Phase 1 imaging data for RAD301 in pancreatic cancer patients](https://longbridge.com/en/news/298445590.md)
- [Lantheus Holdings Discloses Investment at Radiopharm Theranostics with 20.9% Stake](https://longbridge.com/en/news/298075040.md)
- [Biophytis to test BIO101 for limiting weight regain in OBA obesity trial](https://longbridge.com/en/news/298413151.md)
- [Radiopharm schedules FDA end-of-Phase 2 meeting to align Phase 3 trial design for RAD101 brain metastases imaging agent](https://longbridge.com/en/news/296102289.md)
- [NVE Director Daniel A. Baker disposes of 21,140 shares worth $2.15 million](https://longbridge.com/en/news/298523256.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**